Moderate physical activity is necessary and safe for people with cardiovascular (CV) conditions, according to the first sports and exercise guidelines released by the European Society of Cardiology. Clinicians should encourage people with heart disease to exercise moderately most days so that they accumulate at least 150 minutes of exercise per week. Those who are obese, diabetic, or have high blood pressure may benefit most from strength-building exercise such as lifting weights at least 3 times a week, plus moderate or vigorous aerobic exercise. Endurance sports and competitive athletes may require special monitoring and modifications.
Prof. Antonio Pelliccia (Institute of Sports Medicine and Science, Italy) presented the new ESC Guidelines, which will be the benchmark recommendations for future guidelines . The guidelines have included the most current research in exercise in patients with CV disease. Where possible, these new guidelines align with existing ESC Guidelines for the investigation, risk assessment, and management of individuals with cardiovascular diseases to promote exercise programmes and sports participation.
In the first sections, evidence is weighed regarding recreation and competitive sports in the general population, with estimated incidences of CV death in both younger and older athletes with no history of health problems or putative congenital heart syndromes.
The bulk of the guidelines examine evidence of exercise in the clinical setting in patients with CV diseases. The chance of exercise triggering cardiac arrest or heart attack is extremely low, but clinicians should aim to monitor activity intensity and suggest modifications when needed. Special attention is also given to data supporting recommendations for individuals with obesity, hypertension, dyslipidaemia, or diabetes. Importantly, an entire concluding chapter is dedicated to gaps in existing evidence, which may serve as hypothesis-generating for future research.
- Pelliccia A, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. 2020 New ESC Guidelines, ESC Congress 2020, 31 Aug.
- Pelliccia A, et al. Eur Heart J. 2020;ehaa605. DOI:10.1093/eurheartj/ehaa605/5898937.
« 2020 Adult Congenital Heart Disease Guidelines Next Article
2020 Non-ST-Segment Elevation Acute Coronary Syndromes Guidelines »
Table of Contents: ESC 2020
Letter from the Editor
ESC 2020 Highlights Podcast
2020 ESC Clinical Practice Guidelines
2020 Atrial Fibrillation Guidelines
2020 Non-ST-Segment Elevation Acute Coronary Syndromes Guidelines
2020 Sports Cardiology and Exercise in Cardiovascular Patients Guidelines
2020 Adult Congenital Heart Disease Guidelines
Hot Line Presentations
SGLT2 inhibitor improves cardiovascular outcomes in heart failure patients
First-in-class cardiac myosin inhibitor effective in obstructive hypertrophic cardiomyopathy
Reduced cardiovascular outcomes with early rhythm control
Trimetazidine after successful PCI not associated with fewer cardiac events
POPular TAVI: Aspirin-only antiplatelet strategy?
Reduced NT-proBNP in HFpEF with sacubitril/valsartan
DAPA-CKD: Dapagliflozin improves CKD survival ± diabetes
Low-dose colchicine reduces CV death and ischaemic events in coronary disease
Similar outcomes sPESI and HESTIA for pulmonary embolism triage
Antihypertensives also reduce CV risk in people with normal blood pressure
COVID-19: Continuing versus suspending ACE inhibitors and ARBs
Drug initiation strategy not associated with increased use of oral anticoagulants
Restrictive blood transfusion non-inferior and cost-effective strategy
Increased mortality with colchicine in patients with ACS
Rivaroxaban protects limbs and ischaemic events in CAD-PAD patients
Antisense APOC3 oligonucleotide lowers triglyceride and atherogenic lipoproteins
Antisense ANGPTL3 lowers triglycerides
Reduced progression of coronary atherosclerosis with icosapent ethyl
Digoxin improves symptoms in stable patients with permanent AF
SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations
COVID and Cardiovascular Disease
Risk factors for thromboembolism and bleeding in COVID-19: lessons from Wuhan
The Yale COVID-19 Cardiovascular Registry
COVID-19 treatments and the importance of randomised trials